Literature DB >> 34073997

Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B-Loaded Nail Lacquer.

Aleph M S Souza1, Renato C A Ribeiro2, Gleyse K L O Pinheiro3, Francisco I Pinheiro3, Wógenes N Oliveira2, Luanda B F C Souza1, André L Silva4, Lucas Amaral-Machado2, Éverton N Alencar5, Guilherme M Chaves1,2, Eryvaldo S T Egito1,2,5.   

Abstract

Onychomycosis induced by Candida spp. has several limitations regarding its treatment. Nail lacquers display the potential to overcome these drawbacks by providing therapeutic compliance and increasing local drug bioavailability. Thus, this work aimed to produce a nail lacquer loaded with Amphotericin B (AmB) and evaluate its performance. The AmB-loaded nail lacquer was produced and preliminarily characterized. An AmB quantification method was developed. Stability, drug release, permeability and anti-Candida activity assays were conducted. The analytical method validation met the acceptance criteria. The drug loading efficiency was 100% (0.02 mg/g of total product), whereas the AmB stability was limited to ≅7 days (≅90% remaining). The nail lacquer displayed a drying time of 187 s, non-volatile content of around 20%w/w, water-resistance of approximately 2%w/w of weight loss and satisfactory in vitro adhesion. Moreover, the in vitro antifungal activity against different Candida spp. strains was confirmed. The AmB release and the ex vivo permeability studies revealed that AmB leaves the lacquer and permeates the nail matrix in 47.76 ± 0.07% over 24 h. In conclusion, AmB-loaded nail lacquer shows itself as a promising extemporaneous dosage form with remarkable anti-Candida activity related to onychomycosis.

Entities:  

Keywords:  Candida spp.; amphotericin B; extemporaneous product; nail infection; nail lacquer; onychomycosis

Year:  2021        PMID: 34073997     DOI: 10.3390/pharmaceutics13060784

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  39 in total

1.  Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy.

Authors:  F Pittrof; J Gerhards; W Erni; G Klecak
Journal:  Clin Exp Dermatol       Date:  1992-09       Impact factor: 3.470

2.  Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis.

Authors:  Anil Kumar Bhatta; Uma Keyal; Xin Huang; Jing Jun Zhao
Journal:  J Am Acad Dermatol       Date:  2016-02-10       Impact factor: 11.527

Review 3.  Drug delivery to the nail: therapeutic options and challenges for onychomycosis.

Authors:  Bhavesh S Barot; Punit B Parejiya; Hetal K Patel; Dharmik M Mehta; Pragna K Shelat
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2014       Impact factor: 4.889

4.  Unveiling the Amphotericin B Degradation Pathway and Its Kinetics in Lipid-Based Solutions.

Authors:  Éverton N Alencar; Phawanan Sawangchan; Lee E Kirsch; Eryvaldo Sócrates T Egito
Journal:  J Pharm Sci       Date:  2020-11-09       Impact factor: 3.534

Review 5.  Toenail onychomycosis: an important global disease burden.

Authors:  J Thomas; G A Jacobson; C K Narkowicz; G M Peterson; H Burnet; C Sharpe
Journal:  J Clin Pharm Ther       Date:  2010-10       Impact factor: 2.512

6.  Evaluation of topical antifungal products in an in vitro onychomycosis model.

Authors:  Reindert Sleven; Ellen Lanckacker; Peter Delputte; Louis Maes; Paul Cos
Journal:  Mycoses       Date:  2016-02-09       Impact factor: 4.377

7.  Onychomycosis in Cameroon: a clinical and epidemiological study among dermatological patients.

Authors:  Salvador Nkondjo Minkoumou; Valentina Fabrizi; Manuela Papini
Journal:  Int J Dermatol       Date:  2012-12       Impact factor: 2.736

Review 8.  Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes.

Authors:  Tracey C Vlahovic
Journal:  Clin Podiatr Med Surg       Date:  2016-03-26       Impact factor: 1.231

Review 9.  Onychomycosis: a review.

Authors:  A K Gupta; N Stec; R C Summerbell; N H Shear; V Piguet; A Tosti; B M Piraccini
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-05       Impact factor: 6.166

Review 10.  Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.

Authors:  Katarzyna Tabara; Anna E Szewczyk; Wojciech Bienias; Agnieszka Wojciechowska; Marta Pastuszka; Magdalena Oszukowska; Andrzej Kaszuba
Journal:  Postepy Dermatol Alergol       Date:  2015-02-03       Impact factor: 1.837

View more
  2 in total

1.  Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.

Authors:  Daniela Monti; Silvia Tampucci; Valentina Paganini; Susi Burgalassi; Patrizia Chetoni; Jordi Galván; Francesco Celandroni; Emilia Ghelardi
Journal:  Life (Basel)       Date:  2022-05-27

2.  Printing Drugs onto Nails for Effective Treatment of Onychomycosis.

Authors:  Thomas D Pollard; Margherita Bonetti; Adam Day; Simon Gaisford; Mine Orlu; Abdul W Basit; Sudaxshina Murdan; Alvaro Goyanes
Journal:  Pharmaceutics       Date:  2022-02-19       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.